OSE Immunotherapeutics SA
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| OSE.PA | HBP.TO | OSTX | ATORX.ST | CHRS | ACTI.ST | |
|---|---|---|---|---|---|---|
| Market cap | 44.95M | 70.27M | 53.83M | 38.18M | 131.36M | 102.54M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.6 | -8.4 | 3.3 | -0.1 | -1.3 | — |
| Price/book | 1.5 | 4.8 | -4.4 | 0.3 | 2.2 | 2.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −67.06% | −54.68% | −35.56% | −99.44% | −42.95% | −42.74% |
| Today | +3.06% | 0.00% | −0.86% | 0.00% | +5.54% | +5.71% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All OSE.PA news ›OSE Immunotherapeutics SA (ORPOF) Discusses Tedopi in Non-Small Cell Lung Cancer After Chemo-Immunotherapy Transcript
OSE Immunotherapeutics SA (ORPOF) Discusses Tedopi in Non-Small Cell Lung Cancer After Chemo-Immunotherapy November 4, 2026 11:00 AM ESTCompany... OSE Immunotherapeutics SA (ORPOF) Discusses Tedopi in Non-Small Cell Lung Cancer After…
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedica... OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of…
OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
NANTES, France, August 28, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the 'Company'), today announced that th... OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2,…
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Tr
OSE Immunotherapeutics' Tedopi Combination Meets Primary Endpoint In NSCLC Trial
OSE Immunotherapeutics SA (OSE), a clinical-stage biotech company, announced topline results from the Combi-TED academic Phase 2 international clinical trial of Tedopi sponsored by FoRT and evaluating Tedopi (OSE2101), in combination with…
OSE Immunotherapeutics: first patient treated in a Phase 2 study
The biotech company welcomed the announcement by its partner Veloxis Pharmaceuticals, Inc. regarding the treatment of the first patient enrolled in the Phase 2 RENGEVITY-201 clinical trial. The study aims to evaluate Pegrizeprument (also…
Transcript : OSE Immunotherapeutics SA - Special Call
Presenter SpeechMarc Le Bozec Hello, everyone. My name is Marc Le Bozec. I'm the CEO of OSE Immunotherapeutics, which is a listed company on Paris Stock Market. We're very happy and very proud to... Transcript : OSE Immunotherapeutics SA -…
OSE Immunotherapeutics Recovers Following Oddo BHF Endorsement
OSE Immunotherapeutics is trading in the green on the Paris Stock Exchange, potentially snapping a four-session losing streak that saw the stock shed 6.59%.... The biotechnology firm is benefiting from bargain hunting as well as a positive…
OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference
Nantes, France, October 15, 2026 - 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation,…
OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant...
Nantes, France, September 9, 2026 – 6pm CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com8
- markets.businessinsider.com5
- manilatimes.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.